Skip to content

Clinical Trial of Crocus Kozanis Administration in Obese Children and Adolescents

Double-blind Randomized Cross-over Clinical Trial of Crocus Kozanis Administration in Obese Children and Adolescents

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05572749
Enrollment
75
Registered
2022-10-10
Start date
2021-05-01
Completion date
2023-09-30
Last updated
2024-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemias, Obesity, PreDiabetes

Brief summary

The study aims to investigate possible effects of per os Crocus Kozanis administration in children and adolescents with obesity

Interventions

DIETARY_SUPPLEMENTCrocus Kozanis

In this study, intervention will be the administration of Crocus Kozanis dietary supplement. Crocus Kozanis is a herb which is cultivated in Kozani, Greece.

DIETARY_SUPPLEMENTPlacebo of Crocus Kozanis

Placebo of Crocus Kozanis

DRUGMetformin

Metformin will be administered in a dosage of 1000mg per day. Metformin is a formally approved therapy for children with diabetes in Europe.

Sponsors

Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
10 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* Age above 10 year-old * Diagnosis of Obesity according to International Obesity Task Force Criteria * Presence of impaired glucose tolerance and/or impaired fasting glucose

Exclusion criteria

* Overt diabetes (any type) * Diagnosis of any chronic disease * Previous use of dietary supplement with Crocus or Crocus Sativus * Administration of chronic medication

Design outcomes

Primary

MeasureTime frameDescription
Glycemic controlGlycemic control will be assessed for each participant at the beginning of the study and thereafter every 12 weeks, up to 9 months (week 0, week 12, week 24, week 36).Glycemic control will be assessed with glycated hemoglobin (ΗbA1c%) and/or oral glucose tolerance test (OGTT)

Secondary

MeasureTime frameDescription
Lipidemic profileLipidemic profile will be assessed for each participant at the beginning of the study and thereafter every 12 weeks, up to 9 months (week 0, week 12, week 24, week 36).Lipidemic profile will be assessed with levels of cholesterol, triglycerides, HDL and LDL in fasting state

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026